United Kingdom

Sumitomo Chemical Co Ltd (4005.T)

4005.T on Tokyo Stock Exchange

7:00am BST
Change (% chg)

¥-3 (-0.49%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Sumitomo Chemical to acquire 51 pct stake in Wuxi-based electronic materials tech firm
Friday, 18 May 2018 

May 18 (Reuters) - Sumitomo Chemical Co Ltd <4005.T>:Says it plans to acquire 51 percent stake in a Wuxi-based electronic materials technology firm (target firm) on June 4, at an undisclosed price .Says it will indirectly and directly hold 98 percent stake in target firm, up from 47 percent.  Full Article

Carna Biosciences and Sumitomo Dainippon Pharma sign agreement on joint research, development, and commercialization of kinase inhibitors
Tuesday, 27 Mar 2018 

March 27 (Reuters) - Carna Biosciences Inc <4572.T>:Says it and Sumitomo Dainippon Pharma Co Ltd <<<4506.T>>> , signed an agreement on joint research with the aim of discovering novel kinase inhibitors for psychiatric and neurological disorders, as well as on the subsequent development and commercialization of such therapeutic agent.  Full Article

Sumitomo Dainippon Pharma says result of early-retirement program
Monday, 25 Dec 2017 

Dec 25 (Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T> ::Says 86 employees took up the offer of the early-retirement program announced on Sept. 27.Effective date of retirement is March 31, 2018.A premium will be added to the normal retirement allowance of eligible applicants.Says eligible applicants will also have the option to receive job-placement assistance.  Full Article

Sumitomo Chemical Co to buy stake exceeding 80% in Botanical Resources Australia - Nikkei
Tuesday, 21 Nov 2017 

Nov 22 (Reuters) - Nikkei::Sumitomo Chemical Co Ltd to buy a stake exceeding 80% in Botanical Resources Australia for about 15 billion yen - Nikkei.  Full Article

Sumitomo Dainippon Pharma and Angelini Announce Partnership for Commercialization of Latuda (Lurasidone Hydrochloride) in Europe
Tuesday, 21 Nov 2017 

Nov 21 (Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>:Says it and Angelini S.p.A announced today that the companies have formed a partnership with the goal to expand availability in Europe of Latuda®, an atypical antipsychotic which was created by the co .Under the terms of the agreement, Sunovion Pharmaceuticals Europe Ltd., a subsidiary company of Sumitomo Dainippon Pharma Group, has granted Angelini exclusive commercialization rights for LATUDA in 29 European countries and in Turkey.  Full Article

Sumitomo Dainippon Pharma and Poxel announce strategic partnership for development and commercialization of Imeglimin
Monday, 30 Oct 2017 

Oct 30 (Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>:Says it signed an agreement with Poxel SA on Oct. 30, for the development and commercialization of Imeglimin, an investigational therapeutic agent for type 2 diabetes, in Japan, China, South Korea, Taiwan and nine other Southeast Asian countries.Under the Agreement, Poxel SA is entitled to receive an upfront payment of approximately 4.75 billion yen and future potential development milestone payments of up to 2.75 billion yen .  Full Article

Kitasato Institute and Sumitomo Dainippon Pharma signs joint drug discovery research agreement
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>:Says it and the Kitasato Institute have signed a joint drug discovery research agreement for infections caused by bacteria with antimicrobial resistance (AMR).  Full Article

Nufarm extends agreements with Sumitomo Chemical Co​
Monday, 23 Oct 2017 

Oct 24 (Reuters) - Nufarm Ltd ::Signs long-term extension to a series of global collaboration agreements with Sumitomo Chemical Co​.  Full Article

R&I affirms Sumitomo Chemical's rating at "A" and says stable outlook-R&I
Friday, 22 Sep 2017 

Sept 22 (Reuters) - Sumitomo Chemical Co Ltd <4005.T>:* Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A"-R&I.* Rating outlook stable-R&I .  Full Article

Sumitomo Dainippon Pharma U.S.-based unit enters agreement to divest asthma and allergy products to Covis pharma
Friday, 14 Jul 2017 

July 14 (Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>:* Says its U.S.-based unit Sunovion Pharmaceuticals Inc. has.* The transaction is expected to close during the first half of Fiscal Year 2017, subject to customary closing conditions.  Full Article

UPDATE 3-Roundup cancer verdict sends Bayer shares sliding

* Monsanto says to appeal the verdict (Adds loss in market value, analyst quote)